article Open AccessTop 1% cited

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

New England Journal of Medicine · 2015 · Vol. 372(26) · pp. 2509–2520

Dung T. Le✉(Sidney Kimmel Comprehensive Cancer Center)Jennifer N. Uram(Sidney Kimmel Comprehensive Cancer Center)Hao Wang(Sidney Kimmel Comprehensive Cancer Center)Bjarne R. Bartlett(Swim Across America)Holly Kemberling(Sidney Kimmel Comprehensive Cancer Center)Aleksandra Eyring(Sidney Kimmel Comprehensive Cancer Center)Andrew D. Skora(Howard Hughes Medical Institute)Brandon Luber(Sidney Kimmel Comprehensive Cancer Center)Nilofer S. Azad(Sidney Kimmel Comprehensive Cancer Center)Dan Laheru(Sidney Kimmel Comprehensive Cancer Center)Barbara Biedrzycki(Sidney Kimmel Comprehensive Cancer Center)Ross C. Donehower(Sidney Kimmel Comprehensive Cancer Center)Atif Zaheer(Johns Hopkins University)George A. Fisher(Stanford University)Todd S. Crocenzi(Providence Health & Services)James J. Lee(UPMC Hillman Cancer Center)Steven M. Duffy(Virginia Cancer Institute)Richard M. Goldberg(Cancer Genetics (United States))Albert de la Chapelle(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)Minori Koshiji(Merck & Co., Inc., Rahway, NJ, USA (United States))Feriyl Bhaijee(Johns Hopkins Medicine)Thomas Huebner(Johns Hopkins Medicine)Ralph H. Hruban(Johns Hopkins Medicine)Laura D. Wood(Johns Hopkins University)Nathan Cuka(Johns Hopkins University)Drew M. Pardoll(Sidney Kimmel Comprehensive Cancer Center)Nickolas Papadopoulos(Sidney Kimmel Comprehensive Cancer Center)Kenneth W. Kinzler(Sidney Kimmel Comprehensive Cancer Center)Shibin Zhou(Sidney Kimmel Comprehensive Cancer Center)Toby C. Cornish(Johns Hopkins University)Janis M. Taube(Johns Hopkins University)Robert A. Anders(Johns Hopkins Medicine)James R. Eshleman(Johns Hopkins Medicine)Bert Vogelstein(Howard Hughes Medical Institute)Luis A. Díaz

View via DOI Full-text PDF

Abstract

This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; ClinicalTrials.gov number, NCT01876511.).

Genetic factors in colorectal cancer Cancer Immunotherapy and Biomarkers Cancer Genomics and DiagnosticsMedicinePembrolizumabDNA mismatch repairColorectal cancerHazard ratioInternal medicineOncologyCancerImmune checkpointMicrosatellite instability

MeSH terms

AdenocarcinomaAdultAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasm MetastasisColorectal NeoplasmsDisease-Free SurvivalKaplan-Meier EstimateDNA Mismatch RepairProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, Humanized

Citations

9,308

FWCI

589.41

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer